Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The response includes several label-supported statements about liver enzyme abnormalities, dose-related incidence, caution with alcohol/history of liver disease, contraindication of active liver disease, and recommended liver function test timing (prior to and at 12 weeks; periodically thereafter). However, it also contains multiple unsupported or overly specific claims (quantitative alcohol cutoffs; drug class/examples; symptom sign-list beyond jaundice; specific monitoring intervals like “every 6–12 months”; and prescriptive dose-reduction/discontinuation guidance stated as “usually” under a 3–5× ULN threshold).
Category Scores
Accurate Statements
Lipitor (atorvastatin) can raise liver enzymes.
Supported by label statement that statins are associated with biochemical abnormalities of liver function and transaminase elevations (5.2 Liver Dysfunction).
The incidence of persistent elevations (>3 times ULN on 2+ occasions) increases with dose, including 80 mg having the highest incidence (2.3%).
Label provides incidence by dose, including 80 mg (5.2 Liver Dysfunction).
Liver function tests should be performed prior to and at 12 weeks following initiation and any elevation of dose, and periodically thereafter (e.g., semiannually).
Directly stated in 5.2 Liver Dysfunction and reiterated in 17.2 Liver Enzymes.
Lipitor should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.
Stated in 5.2 Liver Dysfunction.
Active liver disease or unexplained persistent transaminase elevations are contraindications to use.
Active liver disease contraindication stated in 4.1 Active Liver Disease and referenced from 5.2.
Patients who develop increased transaminase levels should be monitored until abnormalities resolve; if ALT or AST >3 times ULN persist, reduction of dose or withdrawal is recommended.
Stated in 5.2 Liver Dysfunction.
One patient in clinical trials developed jaundice, and other increases in LFTs were not associated with jaundice or other clinical signs or symptoms.
Stated in 5.2 Liver Dysfunction.
Postmarketing adverse reactions include hepatic failure.
Hepatic failure listed under postmarketing experience (6.2 Postmarketing Experience).
LIPITOR is metabolized by CYP 3A4 and strong CYP 3A4 inhibitors increase atorvastatin plasma concentrations (interaction risk framework).
Stated in 7 and 7.1 Strong Inhibitors of CYP 3A4.
Unsupported Statements
Consuming more than 21 alcoholic drinks per week (men) increases risk of Lipitor liver complications.
No quantitative alcohol cutoffs (by drinks/week) are provided in the provided label text (5.2 only states “substantial quantities of alcohol” with caution).
Consuming more than 14 alcoholic drinks per week (women) increases risk of Lipitor liver complications.
No quantitative alcohol cutoffs are provided in the provided label text.
Taking other drugs that strain the liver (such as certain antibiotics or antifungals) increases risk of Lipitor liver complications.
The provided drug interaction section addresses myopathy risk and strong CYP 3A4 inhibitors by example; it does not support “certain antibiotics or antifungals” as hepatotoxic straining drugs increasing liver complications.
Dark urine is a sign to watch for with Lipitor-related liver issues.
No such symptom is mentioned in the provided label sections (5.2/6.2).
Pale stool is a sign to watch for with Lipitor-related liver issues.
No such symptom is mentioned in the provided label sections.
Unexplained abdominal pain is a sign to watch for with Lipitor-related liver issues.
No such symptom is mentioned in the provided label sections.
A doctor may re-check liver enzymes within a few weeks to see if they return to normal.
Label specifies liver tests prior to and at 12 weeks after initiation and dose elevation, and periodically thereafter; it does not state a “few weeks” recheck plan.
If liver enzymes rise above 3–5 times the upper limit, Lipitor is usually discontinued.
Label states reduction of dose or withdrawal is recommended when ALT/AST >3 times ULN persist; it does not state “usually discontinued” or a 3–5× range threshold.
If liver tests are stable, liver enzyme tests are repeated every 6–12 months.
Label says periodically thereafter and provides an example of semiannually; it does not provide a 6–12 months interval.
Atorvastatin has a comparable liver risk to simvastatin and rosuvastatin.
No cross-statins liver risk comparisons are supported by the provided label text.
Some studies suggest slightly higher liver effect rates at high doses of atorvastatin.
No such study-based statement is supported by the provided label text.
Using the lowest effective dose reduces liver strain with Lipitor.
The label provides dose-dependent incidence data and recommends dose reduction/withdrawal in specific circumstances, but does not state this general causal phrasing.
Incidence of liver effects varies among statins.
No such statement is present in the provided label text.
Lipitor can rarely cause hepatitis.
The provided label text does not use or support the specific claim of “hepatitis” as an adverse outcome; it describes transaminase elevations and jaundice, and postmarketing hepatic failure.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The response does not accurately reproduce the label’s recommended monitoring cadence details (prior to and at 12 weeks; periodically such as semiannually) in a way that matches the label wording, instead giving additional intervals (e.g., “usually 4–12 weeks,” “every 6–12 months”).
Importance:
Moderate
The response states multiple symptom/sign items beyond jaundice; while these are not supported, the label itself does not provide a symptom checklist. A safer label-aligned omission would be to restrict to label-listed clinical sign (jaundice) and monitoring of LFTs.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While general concepts of monitoring liver enzymes, dose-related transaminase elevations, caution with alcohol/history of liver disease, and the contraindication of active liver disease are supported, several quantitative and symptom-based claims are not supported by the provided label text. Overly specific or incorrect monitoring/threshold guidance could mislead interpretation or timing of follow-up relative to the label’s recommendations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided label text, including symptom sign-list items, quantitative alcohol cutoffs, specific drug examples, and monitoring interval/threshold phrasing.
Suggested Improvement
Rephrase to match label wording: (1) monitoring prior to and at 12 weeks after initiation and dose changes and periodically thereafter (e.g., semiannually), (2) caution with substantial alcohol and history of liver disease, (3) contraindication in active liver disease/unexplained persistent transaminase elevations, (4) avoid unsupported quantitative alcohol thresholds, drug examples for liver complications, and non-label symptom checklists; (5) for ALT/AST >3×ULN that persist, state that dose reduction or withdrawal is recommended without adding a 3–5× range or “usually discontinued” language.